J Cardiovasc Electrophysiol 2005;16:1160 5. 262. Gasparini M, Auricchio A, Regoli F, et al. Four-year ef cacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial brillation. J Am Coll Cardiol 2006;48:734 43. 263. Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial brillation: a systematic review and meta-analysis. Heart Rhythm 2011; 8:1088 94. 264. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchro- nization in patients with atrial brillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008;52:1239 46. 265. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable de brillator: the Dual Chamber and VVI Implantable De brillator (DAVID) Trial. JAMA 2002;288:3115 23. 266. Adelstein E, Schwartzman D, Gorcsan J 3rd, et al. Predicting hyper- response among pacemaker-dependent nonischemic cardiomyopathy patients upgraded to cardiac resynchronization. J Cardiovasc Electro- physiol 2011;22:905 11. 267. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol 2009;103: 1280 4. 268. Setoguchi S, Nohria A, Rassen JA, et al. Maximum potential bene t of implantable de brillators in preventing sudden death after hospital admission because of heart failure. CMAJ 2009;180:611 6. 269. Carson P, Anand I, O Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and De brillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46: 2329 34. 270. Zareba W, Piotrowicz K, McNitt S, et al. Implantable cardioverter- de brillator ef cacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). 